BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kendall T, Verheij J, Gaudio E, Evert M, Guido M, Goeppert B, Carpino G. Anatomical, histomorphological and molecular classification of cholangiocarcinoma. Liver Int. 2019;39 Suppl 1:7-18. [PMID: 30882996 DOI: 10.1111/liv.14093] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 33.5] [Reference Citation Analysis]
Number Citing Articles
1 Byrling J, Hilmersson KS, Ansari D, Andersson R, Andersson B. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma. Clin Transl Oncol 2021. [PMID: 34319497 DOI: 10.1007/s12094-021-02685-8] [Reference Citation Analysis]
2 Cholangiocarcinoma Working Group. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part I: Classification, diagnosis and staging. Dig Liver Dis 2020;52:1282-93. [PMID: 32893173 DOI: 10.1016/j.dld.2020.06.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Hubner RA, Reeves HL, Edeline J. Combined hepatocellular-cholangiocarcinoma - More questions than answers. Liver Int 2021;41:1186-8. [PMID: 34002474 DOI: 10.1111/liv.14894] [Reference Citation Analysis]
4 Arabi NA, Abdoun AA, Ali MO, Elhaj SK, Mohd SA. Pancreaticoduodenectomy in a patient with intestinal malrotation and distal cholangiocarcinoma: a case report and review of the literature. J Med Case Rep 2020;14:153. [PMID: 32933586 DOI: 10.1186/s13256-020-02468-9] [Reference Citation Analysis]
5 Vij M, Puri Y, Rammohan A, G G, Rajalingam R, Kaliamoorthy I, Rela M. Pathological, molecular, and clinical characteristics of cholangiocarcinoma: A comprehensive review. World J Gastrointest Oncol 2022; 14(3): 607-627 [DOI: 10.4251/wjgo.v14.i3.607] [Reference Citation Analysis]
6 DeJesus AA, Penninck DG, Webster CR. Ultrasonographic evaluation of cholecystoduodenostomy sites in six cats. J Feline Med Surg 2021;23:194-202. [PMID: 32436775 DOI: 10.1177/1098612X20921062] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Di Matteo S, Nevi L, Overi D, Landolina N, Faccioli J, Giulitti F, Napoletano C, Oddi A, Marziani AM, Costantini D, De Rose AM, Melandro F, Bragazzi MC, Grazi GL, Berloco PB, Giuliante F, Donato G, Moretta L, Carpino G, Cardinale V, Gaudio E, Alvaro D. Metformin exerts anti-cancerogenic effects and reverses epithelial-to-mesenchymal transition trait in primary human intrahepatic cholangiocarcinoma cells. Sci Rep 2021;11:2557. [PMID: 33510179 DOI: 10.1038/s41598-021-81172-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
8 Zhou M, Wang C, Lu S, Xu Y, Li Z, Jiang H, Ma Y. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. EBioMedicine 2021;67:103375. [PMID: 33993051 DOI: 10.1016/j.ebiom.2021.103375] [Reference Citation Analysis]
9 Wu MJ, Shi L, Merritt J, Zhu AX, Bardeesy N. Biology of IDH mutant cholangiocarcinoma. Hepatology 2022. [PMID: 35226770 DOI: 10.1002/hep.32424] [Reference Citation Analysis]
10 Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R. Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. World J Gastrointest Oncol 2021;13:332-50. [PMID: 34040697 DOI: 10.4251/wjgo.v13.i5.332] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
11 Xu S, Guo Y, Zeng Y, Song Z, Zhu X, Fan N, Zhang Z, Ren G, Zang Y, Rao W. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma. BMC Cancer 2021;21:152. [PMID: 33579226 DOI: 10.1186/s12885-021-07792-x] [Reference Citation Analysis]
12 Ma B, Meng H, Tian Y, Wang Y, Song T, Zhang T, Wu Q, Cui Y, Li H, Zhang W, Li Q. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. BMC Cancer 2020;20:318. [PMID: 32293336 DOI: 10.1186/s12885-020-06804-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
13 Mancinelli R, Cutone A, Rosa L, Lepanto MS, Onori P, Pannarale L, Franchitto A, Gaudio E, Valenti P. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma. Eur J Histochem 2020;64. [PMID: 33131269 DOI: 10.4081/ejh.2020.3156] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Wen KW, Rabinovitch PS, Wang D, Mattis AN, Ferrell LD, Choi WT. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions. Virchows Arch 2020;477:527-34. [PMID: 32296928 DOI: 10.1007/s00428-020-02812-w] [Reference Citation Analysis]
15 Katabathina VS, Marji H, Khanna L, Ramani N, Yedururi S, Dasyam A, Menias CO, Prasad SR. Decoding Genes: Current Update on Radiogenomics of Select Abdominal Malignancies. Radiographics 2020;40:1600-26. [PMID: 33001791 DOI: 10.1148/rg.2020200042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
16 Zhang R, Puzzoni M, Mariani S, Zheng Y, Liscia N, Guo Y, Donisi C, Liu Y, Impera V, Fang W, Scartozzi M. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Sci 2021. [PMID: 34534382 DOI: 10.1111/cas.15139] [Reference Citation Analysis]
17 Ma B, Meng H, Shen A, Ma Y, Zhao D, Liu G, Zheng S, Tian Y, Zhang W, Li Q, Li S. Prognostic Value of Inflammatory and Tumour Markers in Small-Duct Subtype Intrahepatic Cholangiocarcinoma after Curative-Intent Resection. Gastroenterol Res Pract 2021;2021:6616062. [PMID: 33833794 DOI: 10.1155/2021/6616062] [Reference Citation Analysis]
18 Safarikia S, Carpino G, Overi D, Cardinale V, Venere R, Franchitto A, Onori P, Alvaro D, Gaudio E. Distinct EpCAM-Positive Stem Cell Niches Are Engaged in Chronic and Neoplastic Liver Diseases. Front Med (Lausanne) 2020;7:479. [PMID: 32984373 DOI: 10.3389/fmed.2020.00479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Crispo F, Pietrafesa M, Condelli V, Maddalena F, Bruno G, Piscazzi A, Sgambato A, Esposito F, Landriscina M. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives. Molecules 2020;25:E3754. [PMID: 32824685 DOI: 10.3390/molecules25163754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Safarpour AR, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A, Abazari MF, Tarkesh F, Shamsaeefar A, Niknam R, Sivandzadeh GR, Lankarani KB, Ejtehadi F. Cholangiocarcinoma and liver transplantation: What we know so far? World J Gastrointest Pathophysiol 2021; 12(5): 84-105 [PMID: 34676129 DOI: 10.4291/wjgp.v12.i5.84] [Reference Citation Analysis]
21 Ioffe D, Phull P, Dotan E. Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review. Cancer Manag Res 2021;13:8085-98. [PMID: 34737637 DOI: 10.2147/CMAR.S276104] [Reference Citation Analysis]
22 Feng M, Pan Y, Kong R, Shu S. Therapy of Primary Liver Cancer. Innovation (N Y) 2020;1:100032. [PMID: 32914142 DOI: 10.1016/j.xinn.2020.100032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
23 Takemura Y, Ojima H, Oshima G, Shinoda M, Hasegawa Y, Kitago M, Yagi H, Abe Y, Hori S, Fujii-Nishimura Y, Kubota N, Masuda Y, Hibi T, Sakamoto M, Kitagawa Y. Gamma-synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma. Cancer Med 2021;10:5599-613. [PMID: 34245137 DOI: 10.1002/cam4.4121] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Archibugi L, Mariani A, Ciambriello B, Petrone MC, Rossi G, Testoni SGG, Carlucci M, Aldrighetti L, Falconi M, Balzano G, Doglioni C, Capurso G, Arcidiacono PG. High sensitivity of ROSE-supported ERCP-guided brushing for biliary strictures. Endosc Int Open 2021;9:E363-70. [PMID: 33655035 DOI: 10.1055/a-1322-2638] [Reference Citation Analysis]
25 Desjonqueres E, Campani C, Marra F, Zucman-Rossi J, Nault JC. Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver Int 2022. [PMID: 34982503 DOI: 10.1111/liv.15152] [Reference Citation Analysis]
26 Charalampakis N, Papageorgiou G, Tsakatikas S, Fioretzaki R, Kole C, Kykalos S, Tolia M, Schizas D. Immunotherapy for cholangiocarcinoma: a 2021 update. Immunotherapy 2021;13:1113-34. [PMID: 34190581 DOI: 10.2217/imt-2021-0126] [Reference Citation Analysis]
27 Beri N. Unmet needs in the treatment of intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements. Future Oncol 2022. [PMID: 35081733 DOI: 10.2217/fon-2021-1089] [Reference Citation Analysis]
28 Makiuchi T, Sobue T. Descriptive epidemiology of biliary tract cancer incidence and geographic variation in Japan. Eur J Cancer Prev 2022. [PMID: 35485392 DOI: 10.1097/CEJ.0000000000000758] [Reference Citation Analysis]
29 González MI, Vannan DT, Eksteen B, Flores-sotelo I, Reyes JL. Mast Cells in Immune-Mediated Cholangitis and Cholangiocarcinoma. Cells 2022;11:375. [DOI: 10.3390/cells11030375] [Reference Citation Analysis]
30 Augustin J, Gabignon C, Scriva A, Menu L, Calmel C, Scatton O, Paye F, Fléjou JF, Praz F, Cervera P, Wendum D. Testing for ROS1, ALK, MET, and HER2 rearrangements and amplifications in a large series of biliary tract adenocarcinomas. Virchows Arch 2020;477:33-45. [PMID: 32447492 DOI: 10.1007/s00428-020-02822-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Haghbin H, Aziz M. Artificial intelligence and cholangiocarcinoma: Updates and prospects. World J Clin Oncol 2022; 13(2): 125-134 [DOI: 10.5306/wjco.v13.i2.125] [Reference Citation Analysis]
32 Pavicevic S, Reichelt S, Uluk D, Lurje I, Engelmann C, Modest DP, Pelzer U, Krenzien F, Raschzok N, Benzing C, Sauer IM, Stinzing S, Tacke F, Schöning W, Schmelzle M, Pratschke J, Lurje G. Prognostic and Predictive Molecular Markers in Cholangiocarcinoma. Cancers 2022;14:1026. [DOI: 10.3390/cancers14041026] [Reference Citation Analysis]
33 Boyd LNC, Peters GJ, Kazemier G, Giovannetti E. NUC-1031 in biliary tract cancer: from bench to bedside and back? Cancer Chemother Pharmacol 2020;85:1011-4. [PMID: 32476108 DOI: 10.1007/s00280-020-04080-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Louis C, Papoutsoglou P, Coulouarn C. Molecular classification of cholangiocarcinoma. Curr Opin Gastroenterol. 2020;36: 57-62. [PMID: 31895230 DOI: 10.1097/mog.0000000000000611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
35 Kamp EJCA, Dinjens WNM, Doukas M, Bruno MJ, de Jonge PJF, Peppelenbosch MP, de Vries AC. Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures. Therap Adv Gastroenterol 2021;14:17562848211002023. [PMID: 33948111 DOI: 10.1177/17562848211002023] [Reference Citation Analysis]
36 Trifylli E, Koustas E, Papadopoulos N, Sarantis P, Aloizos G, Damaskos C, Garmpis N, Garmpi A, Karamouzis MV. An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma. Life 2022;12:665. [DOI: 10.3390/life12050665] [Reference Citation Analysis]
37 Sarcognato S, Sacchi D, Fassan M, Fabris L, Cadamuro M, Zanus G, Cataldo I, Capelli P, Baciorri F, Cacciatore M, Guido M. Cholangiocarcinoma. Pathologica 2021;113:158-69. [PMID: 34294934 DOI: 10.32074/1591-951X-252] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Bednarsch J, Tan X, Czigany Z, Liu D, Lang SA, Sivakumar S, Kather JN, Appinger S, Rosin M, Boroojerdi S, Dahl E, Gaisa NT, den Dulk M, Coolsen M, Ulmer TF, Neumann UP, Heij LR. The Presence of Small Nerve Fibers in the Tumor Microenvironment as Predictive Biomarker of Oncological Outcome Following Partial Hepatectomy for Intrahepatic Cholangiocarcinoma. Cancers (Basel) 2021;13:3661. [PMID: 34359564 DOI: 10.3390/cancers13153661] [Reference Citation Analysis]
39 Malenica I, Donadon M, Lleo A. Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine. Cancers (Basel) 2020;12:E2190. [PMID: 32781527 DOI: 10.3390/cancers12082190] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
40 Waddell SH, Boulter L. Developing models of cholangiocarcinoma to close the translational gap in cancer research. Expert Opin Investig Drugs 2021;30:439-50. [PMID: 33513027 DOI: 10.1080/13543784.2021.1882993] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Izumiya M, Kato S, Hippo Y. Recent Advances in Implantation-Based Genetic Modeling of Biliary Carcinogenesis in Mice. Cancers (Basel) 2021;13:2292. [PMID: 34064809 DOI: 10.3390/cancers13102292] [Reference Citation Analysis]
42 Boilève A, Verlingue L, Hollebecque A, Boige V, Ducreux M, Malka D. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. Expert Opin Investig Drugs 2021;30:401-9. [PMID: 33641556 DOI: 10.1080/13543784.2021.1896703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Guo X, Shen W. Latest evidence on immunotherapy for cholangiocarcinoma.Oncol Lett. 2020;20:381. [PMID: 33154779 DOI: 10.3892/ol.2020.12244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
44 Aguado-Fraile E, Tassinari A, Ishii Y, Sigel C, Lowery MA, Goyal L, Gliser C, Jiang L, Pandya SS, Wu B, Bardeesy N, Choe S, Deshpande V. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma. Future Oncol 2021;17:2057-74. [PMID: 33709779 DOI: 10.2217/fon-2020-1274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Thol F, Gairing SJ, Czauderna C, Thomaidis T, Gamstätter T, Huber Y, Vollmar J, Lorenz J, Michel M, Bartsch F, Müller L, Kloeckner R, Galle PR, Wörns M, Marquardt JU, Moehler M, Weinmann A, Foerster F. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. JHEP Reports 2022;4:100417. [DOI: 10.1016/j.jhepr.2021.100417] [Reference Citation Analysis]
46 Ju JY, Dibbern ME, Mahadevan MS, Fan J, Kunk PR, Stelow EB. Mismatch Repair Protein Deficiency/Microsatellite Instability Is Rare in Cholangiocarcinomas and Associated With Distinctive Morphologies. Am J Clin Pathol 2020;153:598-604. [PMID: 31844887 DOI: 10.1093/ajcp/aqz199] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Loeffler MA, Hu J, Kirchner M, Wei X, Xiao Y, Albrecht T, De La Torre C, Sticht C, Banales JM, Vogel MN, Pathil-Warth A, Mehrabi A, Hoffmann K, Rupp C, Köhler B, Springfeld C, Schirmacher P, Ji J, Roessler S, Goeppert B. miRNA profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the miR-451a/ATF2 axis. J Pathol 2020;252:239-51. [PMID: 32710569 DOI: 10.1002/path.5514] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
48 Xu X, Chen D, Feng X, Hu J, Ge J, Yan C, Zhang D, Ling Z, Chen J, Wu J. Apolipoprotein B Is Associated With the Microenvironment of Cholangiocarcinoma. Front Oncol 2021;11:654689. [PMID: 33954113 DOI: 10.3389/fonc.2021.654689] [Reference Citation Analysis]
49 Chiow SM, Khoo HW, Low JK, Tan CH, Low HM. Imaging mimickers of cholangiocarcinoma: a pictorial review. Abdom Radiol. [DOI: 10.1007/s00261-021-03399-9] [Reference Citation Analysis]
50 Yoshida N, Aoyagi T, Kimura Y, Naito Y, Izuwa A, Mizoguchi K, Ishii K, Tanaka Y, Ohnishi E, Miura S, Shimamura S, Shirahama N, Kaneshiro K, Saruwatari A, Iwanaga A, Sadakari Y, Hirokata G, Ogata T, Taniguchi M. A rare case of symptomatic grossly-visible biliary intraepithelial neoplasia mimicking cholangiocarcinoma. World J Surg Oncol 2019;17:191. [PMID: 31711502 DOI: 10.1186/s12957-019-1737-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Ninfole E, Pinto C, Benedetti A, Marzioni M, Maroni L. Role of autophagy in cholangiocarcinoma: Pathophysiology and implications for therapy. World J Clin Cases 2021; 9(22): 6234-6243 [PMID: 34434990 DOI: 10.12998/wjcc.v9.i22.6234] [Reference Citation Analysis]
52 Bagante F, Spolverato G, Ruzzenente A, Luchini C, Tsilimigras DI, Campagnaro T, Conci S, Corbo V, Scarpa A, Guglielmi A, Pawlik TM. Artificial neural networks for multi-omics classifications of hepato-pancreato-biliary cancers: towards the clinical application of genetic data. Eur J Cancer 2021;148:348-58. [PMID: 33774439 DOI: 10.1016/j.ejca.2021.01.049] [Reference Citation Analysis]
53 Ntanasis-Stathopoulos I, Tsilimigras DI, Gavriatopoulou M, Schizas D, Pawlik TM. Cholangiocarcinoma: investigations into pathway-targeted therapies. Expert Rev Anticancer Ther 2020;20:765-73. [PMID: 32757962 DOI: 10.1080/14737140.2020.1807333] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
54 Zheng YW, Miao XY, Xiong L, Chen B, Kong FH, Zhou JJ, Liu ZT, Wen Y, Zhang ZJ, Zou H. Sulfasalazine Sensitizes Polyhematoporphyrin-Mediated Photodynamic Therapy in Cholangiocarcinoma by Targeting xCT. Front Pharmacol 2021;12:723488. [PMID: 34483935 DOI: 10.3389/fphar.2021.723488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Zhang X, Zhao Y, Wang W, Yu S, Liu L, Sun D, Li W, Jiang X. Upregulation of circ_0059961 suppresses cholangiocarcinoma development by modulating miR-629-5p/SFRP2 axis. Pathology - Research and Practice 2022. [DOI: 10.1016/j.prp.2022.153901] [Reference Citation Analysis]
56 Bekric D, Neureiter D, Ritter M, Jakab M, Gaisberger M, Pichler M, Kiesslich T, Mayr C. Long Non-Coding RNAs in Biliary Tract Cancer-An Up-to-Date Review. J Clin Med 2020;9:E1200. [PMID: 32331331 DOI: 10.3390/jcm9041200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. Journal of Hepatology 2020;72:353-63. [DOI: 10.1016/j.jhep.2019.10.009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 28.0] [Reference Citation Analysis]
58 Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer.Lancet. 2021;397:428-444. [PMID: 33516341 DOI: 10.1016/S0140-6736(21)00153-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 23.0] [Reference Citation Analysis]
59 Gringeri E, Gambato M, Sapisochin G, Ivanics T, Lynch EN, Mescoli C, Burra P, Cillo U, Russo FP. Cholangiocarcinoma as an Indication for Liver Transplantation in the Era of Transplant Oncology. J Clin Med 2020;9:E1353. [PMID: 32380750 DOI: 10.3390/jcm9051353] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
60 Li Q, Che F, Wei Y, Jiang HY, Zhang Y, Song B. Role of noninvasive imaging in the evaluation of intrahepatic cholangiocarcinoma: from diagnosis and prognosis to treatment response. Expert Rev Gastroenterol Hepatol 2021;15:1267-79. [PMID: 34452581 DOI: 10.1080/17474124.2021.1974294] [Reference Citation Analysis]
61 Moeini A, Haber PK, Sia D. Cell of origin in biliary tract cancers and clinical implications. JHEP Rep 2021;3:100226. [PMID: 33665585 DOI: 10.1016/j.jhepr.2021.100226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
62 Byrling J, Sasor A, Nilsson J, Said Hilmersson K, Andersson R, Andersson B. Expression of peritumoral SPARC during distal cholangiocarcinoma progression and correlation with outcome. Scand J Gastroenterol 2020;55:725-31. [PMID: 32543919 DOI: 10.1080/00365521.2020.1774923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Choe JW, Kim HJ, Kim JS. Survival improvement and prognostic factors in recent management of extrahepatic cholangiocarcinoma: A single-center study. Hepatobiliary Pancreat Dis Int 2020;19:153-6. [PMID: 31974040 DOI: 10.1016/j.hbpd.2019.12.011] [Reference Citation Analysis]
64 Zhang T, Zhang S, Jin C, Lin Z, Deng T, Xie X, Deng L, Li X, Ma J, Ding X, Liu Y, Shan Y, Yu Z, Wang Y, Chen G, Li J. A Predictive Model Based on the Gut Microbiota Improves the Diagnostic Effect in Patients With Cholangiocarcinoma. Front Cell Infect Microbiol 2021;11:751795. [PMID: 34888258 DOI: 10.3389/fcimb.2021.751795] [Reference Citation Analysis]
65 Baiocchi L, Sato K, Ekser B, Kennedy L, Francis H, Ceci L, Lenci I, Alvaro D, Franchitto A, Onori P, Gaudio E, Wu C, Chakraborty S, Glaser S, Alpini G. Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy. Expert Opin Investig Drugs 2021;30:365-75. [PMID: 33226854 DOI: 10.1080/13543784.2021.1854725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
66 Baiocchi L, Lenci I, Milana M, Kennedy L, Sato K, Zhang W, Ekser B, Ceci L, Meadows V, Glaser S, Alpini G, Francis H. Cyclic AMP Signaling in Biliary Proliferation: A Possible Target for Cholangiocarcinoma Treatment? Cells 2021;10:1692. [PMID: 34359861 DOI: 10.3390/cells10071692] [Reference Citation Analysis]
67 Suda R, Sakai N, Matsushita K, Ishige T, Kawasaki Y, Shiko Y, Furukawa K, Mishima T, Nakadai E, Ohtsuka M. Prediction of mismatch repair deficient biliary tract cancer: Role of morphological features and host immune response detected by routine hematoxylin-eosin staining. J Hepatobiliary Pancreat Sci 2021;28:680-91. [PMID: 33998775 DOI: 10.1002/jhbp.988] [Reference Citation Analysis]
68 Boilève A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D. Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:1569. [PMID: 33805461 DOI: 10.3390/cancers13071569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
69 Macias RIR, Cardinale V, Kendall TJ, Avila MA, Guido M, Coulouarn C, Braconi C, Frampton AE, Bridgewater J, Overi D, Pereira SP, Rengo M, Kather JN, Lamarca A, Pedica F, Forner A, Valle JW, Gaudio E, Alvaro D, Banales JM, Carpino G. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut 2022:gutjnl-2022-327099. [PMID: 35580963 DOI: 10.1136/gutjnl-2022-327099] [Reference Citation Analysis]
70 Song G, Shi Y, Meng L, Ma J, Huang S, Zhang J, Wu Y, Li J, Lin Y, Yang S, Rao D, Cheng Y, Lin J, Ji S, Liu Y, Jiang S, Wang X, Zhang S, Ke A, Wang X, Cao Y, Ji Y, Zhou J, Fan J, Zhang X, Xi R, Gao Q. Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma. Nat Commun 2022;13:1642. [PMID: 35347134 DOI: 10.1038/s41467-022-29164-0] [Reference Citation Analysis]
71 Liao C, Wang D, Huang L, Bai Y, Yan M, Zhou S, Qiu F, Lai Z, Wang Y, Tian Y, Zheng X, Chen S. A new strategy of laparoscopic anatomical hemihepatectomy guided by the middle hepatic vein combined with transhepatic duct lithotomy for complex hemihepatolithiasis: A propensity score matching study. Surgery 2021;170:18-29. [PMID: 33589245 DOI: 10.1016/j.surg.2020.12.043] [Reference Citation Analysis]
72 Li H, Qu L, Zhang H, Liu J, Zhang X. A comprehensive transcriptomic landscape of cholangiocarcinoma based on bioinformatics analysis from large cohort of patients. Sci Rep 2021;11:13713. [PMID: 34211100 DOI: 10.1038/s41598-021-93250-4] [Reference Citation Analysis]
73 Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557-588. [PMID: 32606456 DOI: 10.1038/s41575-020-0310-z] [Cited by in Crossref: 160] [Cited by in F6Publishing: 167] [Article Influence: 80.0] [Reference Citation Analysis]
74 Gao Z, Wang J, Shen S, Bo X, Suo T, Ni X, Liu H, Huang L, Liu H. The impact of preoperative biliary drainage on postoperative outcomes in patients with malignant obstructive jaundice: a retrospective analysis of 290 consecutive cases at a single medical center. World J Surg Oncol 2022;20:7. [PMID: 34991594 DOI: 10.1186/s12957-021-02476-z] [Reference Citation Analysis]
75 Wu ZY, Shen W, Yue JQ, Yao WY, Liu SL, Jin YP, Dong P, Ma F, Wu XS, Gong W. Combining Immunoscore with Clinicopathologic Features in Cholangiocarcinoma: An Influential Prognostic Nomogram. Onco Targets Ther 2020;13:11359-76. [PMID: 33192071 DOI: 10.2147/OTT.S274754] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Zaccari P, Cardinale V, Severi C, Pedica F, Carpino G, Gaudio E, Doglioni C, Petrone MC, Alvaro D, Arcidiacono PG, Capurso G. Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas. World J Gastroenterol 2019; 25(31): 4343-4359 [PMID: 31496617 DOI: 10.3748/wjg.v25.i31.4343] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
77 Zhang PJ, Liu MD, Fan FY, Liu KX. A Study on Mesoporous Silica Loaded With Novel Photosensitizers HCE6 and Oxaliplatin for the Treatment of Cholangiocarcinoma. Front Oncol 2021;11:665182. [PMID: 34268112 DOI: 10.3389/fonc.2021.665182] [Reference Citation Analysis]
78 Tomacha J, Dokduang H, Padthaisong S, Namwat N, Klanrit P, Phetcharaburanin J, Wangwiwatsin A, Khampitak T, Koonmee S, Titapun A, Jarearnrat A, Khuntikeo N, Loilome W. Targeting Fatty Acid Synthase Modulates Metabolic Pathways and Inhibits Cholangiocarcinoma Cell Progression. Front Pharmacol 2021;12:696961. [PMID: 34421595 DOI: 10.3389/fphar.2021.696961] [Reference Citation Analysis]
79 Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res 2021;149:321-87. [PMID: 33579427 DOI: 10.1016/bs.acr.2020.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]